NOW: THE PARTICIPATORY MARKETPLACE FOR A TOURIST DESTINATION

Framing metamorphosis: In a unique, bottom-up, destination management case - exploiting mobileinternet based communication – operators’ competition is washed out, in favour of shared sense making, cooperation, and coordination. How is it possible? What are the drivers, enablers, and success factors? What makes it sustainable? What produces shared self-awareness in the community, to gain group access to online trade? What magic organisational intervention produces the “miracle”? Different perspectives: Qualitative analysis interpretation, in a soft, participated, action-case, yields: from a socio-technical perspective: local dimension and participation (sustainability of solution, convenience; a working online market; putting the tourist at centre); from a social perspective: adapt to various users\u27 situation (location, context, and mood; don’t take all, select on quality; crossmarketing partnership); from an IS discipline perspective: social-practice-design intervention; mobile- Internet driven business-model and cooperation; APPs and user configurability. Theory stands: Digging into the conceptual fabrics of the case, unquestionably unveils the embodiment of some anticipated, crisp, phenomenology-based IS concepts, in the social structuration back-bones of human behaviour of NOW: i) personal sense making and motivation (situation, context and mood, convenience, sustainability); ii) people participation to technology-based innovation (participatory-design, constructing well functioning socio-technical infrastructures, user-design in use); iii) intervention for consensus-based, organizational change by social-practice-design (facilitation for shared sense making, trust and cooperation building, bottom-up governance)

Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis

Many clinical trials have investigated the role of ICIs in PM, with contrasting results. We performed a systematic review and meta-analysis of clinical trials testing single-agent anti-Programmed Death -1 (PD-1)/Programmed Death-Ligand 1 (PD-L1), anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) or combined treatment in PM patients, analyzing response and survival rate as well as safety data. We selected 17 studies including 2328 patients. Both OS and PFS rates were significantly higher with combined ICI treatments than with single agent anti-PD-1/PD-L1 (p < 0.001 and p = 0.006, respectively) or anti CTLA-4 (p < 0.001) treatments. ORR and DCR for all ICI treatments were 20% (95% CI 13–27%) and 56% (95% CI 45–67%), respectively, and they did not significantly differ between combined and single agent treatments (p = 0.088 and p = 0.058, respectively). The 12-month OS and 6-month PFS rates did not differ significantly (p = 0.0545 and p = 0.1464, respectively) among pre-treated or untreated patients. Combined ICI treatments had a significantly higher rate of Adverse Events (AEs) (p = 0.01). PD-L1-positive patients had a higher probability of response and survival. In conclusion, combined ICI treatments have higher efficacy than single agents but are limited by higher toxicity. Efficacy was independent of treatment line, so a customized sequential strategy should still be speculated. PD-L1 expression could influence response to ICIs; however, reliable biomarkers are warranted

Association between Peri-Implant Soft Tissue Health and Different Prosthetic Emergence Angles in Esthetic Areas: Digital Evaluation after 3 Years' Function

Background: The aim of the present retrospective study was to assess peri-implant soft tissue health for implants restored with different prosthetic emergence profile angles. Methods: Patients were treated with implants supporting fixed dentures and were followed for 3 years. Buccal emergence angle (EA) measured at 3 years of follow-up visits (t1) were calculated for two different groups: Group 1 (153 implants) for restorations with angle between implant axis and prosthetic emergence angle from >= 30 degrees, and Group 2 (67 implants) for those with angle <= 30 degrees, respectively. Image J software was used for the measurements. Moreover, peri-implant soft tissue parameters such as pocket probing depth (PPD), plaque index (PI) and gingival index (GI) were assessed, respectively. Results: A total of 57 patients were included in the analysis and a total of 220 implants were examined. Mean (+/- SD) EA in Groups 1 and 2 was 46.4 +/- 12.2 and 24.5 +/- 4.7 degrees, respectively. After 3 years of follow-up, a PPD difference of 0.062 mm (CI95% -0.041 mm; 0.164 mm) was calculated between the two groups and was not statistically significant (p = 0.238). Similar results were found for PI (OR = 0.78, CI95% 0.31; 1.98, p = 0.599). Furthermore, GI scores of 2 and 3 were found for nine implants (5.9%) in Group 1, and for five implants in Group 2 (7.5%). A non-significant difference (p = 0.76) was found. Conclusions: Peri-implant soft-tissue health does not seem to be influenced by EA itself, when a proper emergence profile is provided for implant-supported reconstructions in anterior areas

Evidence for Cholecystokinin-Dopamine Receptor Interactions in the Central Nervous System of the Adult and Old Rat: Studies on Their Functional Meaning

info:eu-repo/semantics/publishe

Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner.

The soy isoflavone genistein targets adipose tissue and elicits physiological effects that may vary based on dietary intake. We hypothesized that the adipose effects of genistein are dose and gender dependent. Four-week-old C57BL/6 male and female mice received daily oral doses of genistein (50–200,000 g/kgd) or 17-estradiol (E2) (5 g/kgd) for 15 d or a diet containing 800 ppm genistein. Genistein increased epididymal and renal fat pad and adipocyte size at doses up to 50,000 g/kgd or at 800 ppm in the diet in males but not in females. The alteration in adipocity correlated with changes in peripheral insulin resistance. These treatments increased genistein serum concentrations from 356 to 10326 nM 12 h after treatment and lowered plasma triglycerides and cholesterol levels. The 200,000 g/kgd genistein dose decreased adipose tissue weight similarly to E2. This genistein dose downregulated estrogen receptor ( more than) and progesterone receptor expression and induced estrogen-dependent adipose differentiation factors; it did not change expression of the minimal consensus estrogen-responsive element in ERE-tKLUC mice, which was positively modulated in other tissues (e.g. the lung). E2 down-regulated almost all examined adipogenic factors. Gene microarray analysis identified factors in fat metabolism and obesity-related phenotypes differentially regulated by low and high doses of genistein, uncovering its adipogenic and antiadipogenic actions. The lower dose induced the phospholipase A2 group 7 and the phospholipid transfer protein genes; the 200,000 g/kgd dose inhibited them. The antiadipogenic action of genistein and down-regulation of adipogenic genes required the expression ofER. In conclusion, nutritional doses of genistein are adipogenic in a gender-specific manner, whereas pharmacological doses inhibited adipose deposition